<unk> , sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc.<unk>  acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.<unk>  could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.
Brigatinib
Tucatinib
Selpercatinib
Fostamatinib
Neratinib
Lapatinib
Capmatinib
Infigratinib